{"title":"他莫昔芬治疗失败的乳腺癌患者对托瑞米芬(Fc-1157a)治疗的反应。初步的沟通","authors":"S.R. Ebbs, J. Roberts, M. Baum","doi":"10.1016/0022-4731(90)90016-L","DOIUrl":null,"url":null,"abstract":"<div><p>Nine patients with measurable lesions of locally advanced or recurrent breast cancer have been treated with toremifene 200 mg daily. A response rate of 33% [complete remission (CR) + partial remission (PR)] or 78% [CR + PR + no change (NC)] has been achieved so far. As all our patients had previously relapsed on anti-oestrogen therapy (tamoxifen), we postulate that our response rate was achieved by a direct oncolytic effect.</p></div>","PeriodicalId":17138,"journal":{"name":"Journal of steroid biochemistry","volume":"36 3","pages":"Page 239"},"PeriodicalIF":0.0000,"publicationDate":"1990-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0022-4731(90)90016-L","citationCount":"21","resultStr":"{\"title\":\"Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication\",\"authors\":\"S.R. Ebbs, J. Roberts, M. Baum\",\"doi\":\"10.1016/0022-4731(90)90016-L\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Nine patients with measurable lesions of locally advanced or recurrent breast cancer have been treated with toremifene 200 mg daily. A response rate of 33% [complete remission (CR) + partial remission (PR)] or 78% [CR + PR + no change (NC)] has been achieved so far. As all our patients had previously relapsed on anti-oestrogen therapy (tamoxifen), we postulate that our response rate was achieved by a direct oncolytic effect.</p></div>\",\"PeriodicalId\":17138,\"journal\":{\"name\":\"Journal of steroid biochemistry\",\"volume\":\"36 3\",\"pages\":\"Page 239\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0022-4731(90)90016-L\",\"citationCount\":\"21\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of steroid biochemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/002247319090016L\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of steroid biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/002247319090016L","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication
Nine patients with measurable lesions of locally advanced or recurrent breast cancer have been treated with toremifene 200 mg daily. A response rate of 33% [complete remission (CR) + partial remission (PR)] or 78% [CR + PR + no change (NC)] has been achieved so far. As all our patients had previously relapsed on anti-oestrogen therapy (tamoxifen), we postulate that our response rate was achieved by a direct oncolytic effect.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
